S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Accuray Stock Forecast, Price & News

-0.22 (-4.43 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $4.75
50-Day Range
MA: $4.47
52-Week Range
Now: $4.75
Volume677,815 shs
Average Volume693,681 shs
Market Capitalization$433.53 million
P/E Ratio33.93
Dividend YieldN/A
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
Accuray logo


Overall MarketRank

2.05 out of 5 stars

Medical Sector

24th out of 1,558 stocks

Surgical & Medical Instruments Industry

4th out of 137 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ARAY



Sales & Book Value

Annual Sales$382.93 million
Cash Flow$0.02 per share
Book Value$0.70 per share


Net Income$3.83 million


Market Cap$433.53 million
Next Earnings Date1/27/2021 (Confirmed)
-0.22 (-4.43 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Accuray (NASDAQ:ARAY) Frequently Asked Questions

How has Accuray's stock price been impacted by Coronavirus (COVID-19)?

Accuray's stock was trading at $2.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARAY stock has increased by 109.3% and is now trading at $4.75.
View which stocks have been most impacted by COVID-19

Is Accuray a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Accuray stock.
View analyst ratings for Accuray
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Accuray?

Wall Street analysts have given Accuray a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Accuray wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Accuray's next earnings date?

Accuray is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Accuray

How can I listen to Accuray's earnings call?

Accuray will be holding an earnings conference call on Wednesday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings data on Thursday, August, 13th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01. The medical equipment provider earned $94.98 million during the quarter, compared to the consensus estimate of $99.40 million. Accuray had a return on equity of 4.33% and a net margin of 3.41%. During the same quarter in the prior year, the business posted ($0.02) earnings per share.
View Accuray's earnings history

What price target have analysts set for ARAY?

4 analysts have issued 12 month target prices for Accuray's shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Accuray's stock price to reach $8.00 in the next year. This suggests a possible upside of 68.4% from the stock's current price.
View analysts' price targets for Accuray
or view Wall Street analyst' top-rated stocks.

Who are some of Accuray's key competitors?

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

Who are Accuray's key executives?

Accuray's management team includes the following people:
  • Mr. Joshua H. Levine, Pres, CEO & Director (Age 62, Pay $739.26k)
  • Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 47, Pay $420.51k)
  • Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer (Age 49, Pay $395.87k)
  • Mr. Jesse Chew, Sr. VP, Gen. Counsel & Corp. Sec. (Age 39, Pay $396.02k)
  • Ms. Suzanne Winter, Chief Commercial Officer and Sr. VP of R&D (Age 57, Pay $657.6k)
  • Mr. Michael Hoge, Sr. VP of Global Operations
  • Ken Mobeck, VP of Fin. & Investor Relations
  • Beth Kaplan, PR Director
  • Mr. Scott Chapman, Sr. VP of Global Service
  • Mr. Jim Dennison, Sr. VP of Global Quality & Regulatory Affairs

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kovack Advisors Inc. (0.66%) and Diversified Trust Co (0.03%). Company insiders that own Accuray stock include Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends for Accuray

Which major investors are buying Accuray stock?

ARAY stock was purchased by a variety of institutional investors in the last quarter, including Kovack Advisors Inc., and Diversified Trust Co.
View insider buying and selling activity for Accuray
or or view top insider-buying stocks.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $4.75.

How big of a company is Accuray?

Accuray has a market capitalization of $433.53 million and generates $382.93 million in revenue each year. The medical equipment provider earns $3.83 million in net income (profit) each year or ($0.08) on an earnings per share basis. Accuray employs 932 workers across the globe.

What is Accuray's official website?

The official website for Accuray is www.accuray.com.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.